Prevention of Osteoporosis in Men With Prostate Cancer
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this two year study is to examine the safety and effectiveness of alendronate
(Fosamax) for the prevention of bone loss in men with prostate cancer who are on therapy to
lower their testosterone levels. All men will receive appropriate calcium and vitamin D
supplements and one to two years of alendronate therapy. Bone density tests will be done
every six months.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)